Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

MetaVia Inc.

NASDAQ: MTVA · Life Sciences · 8 alerts · CIK 1638287

Share price
$1.21Close, Nov 16
Market cap
$8.13M
Shares outstanding
6.74MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All MetaVia Inc. filings on SEC EDGAR ↗

8:37 AM ET 10-Q
Financial Results

MetaVia Q3 2026 Results: Net Loss of $4.62M, Loss Widens

MetaVia Inc. reported a net loss of $13.8 million for the nine months ended September 30, 2026, compared to $11.0 million in the prior year, driven by increased research and development expenses. The company's cash position decreased to $8.8 million from $10.3 million at year-end 2025, while total stockholders' equity fell to $2.4 million.

Key figure
Net loss $4.62M
8:36 AM ET 8-K
Financial Results

MetaVia Financial Results

MetaVia Inc. reported third quarter 2026 financial results and provided a corporate update on its clinical pipeline, including positive Phase 1 interim data for DA-1726 in liver-related cardiometabolic diseases. The company also announced the appointment of Dr. Sarah Browne as Chief Medical Officer and plans to initiate a Phase 2 study in MetALD and ALD in the second half of 2027.

Term
Q3 2026

“The positive interim results from our Phase 1 Part 3B study of DA-1726, a novel oxyntomodulin (OXM) analog and dual GLP-1/glucagon receptor agonist, were recently highlighted in an oral presentation at the Precision Liver Symposium. We believe these findings provide important clinical support for DA-1726's potential to treat metabolic dysfunction and alcohol-associated liver disease (MetALD), as well as alcohol-associated liver disease (ALD).”

Hyung Heon Kim, President and Chief Executive Officer

“Last month, we also expanded our clinical leadership team with the appointment of Sarah Browne, M.D., as Chief Medical Officer. Sarah brings more than 20 years of experience spanning clinical development, regulatory science and clinical medicine, including leading the development of pemvidutide, a dual GLP-1/glucagon receptor agonist, through Phase 2 and establishing Phase 3 development strategies.”

Hyung Heon Kim, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.